OBJECTIVES Health care providers who complete this course will be able to: 1. Describe the epidemiology and natural history of type 2 diabetes. 2. Diagnosis and manage type 2 diabetes throughout the lifespan. 3. Apply the Chronic Care Model and team approach in managing type 2 diabetes. 4. Explain the latest guidelines as described in the ADA 2008 Standards of Diabetes Care in Diabetes across the lifespan. 5. Utilize appropriate National Diabetes Education Program (NDEP) educational materials for diabetes prevention and control. This Special Workshop will take place on Saturday July 25, 2009 at 7:30 am – 1:00 pm.
INTENDED AUDIENCE The 2009 NMA Convention and Scientific Assembly has planned as an educational enrichment for practicing physicians, residents and other health professionals representing a variety of medical specialties and related health professions. Participants in the National Medical Association’s Annual Convention and Scientific Assembly held in Las Vegas, Nevada, July 25-29, 2009 will include physicians, allied health professionals, residents, medical students and health advocates.
Intended Audience: This program is intended for primary care and family medicine physicians, internists, nurse practitioners and other healthcare professionals interested in diabetes.
Objectives Following participation in this session, attendees should be able to: 1) understand the supportive evidence for diabetes care provided in the national practice guidelines, 2) evaluate relevant multiple mechanisms that progress to Type 2 diabetes, and 3) discuss solutions and challenges that impact the multidisciplinary team providing diabetes.
Intended Audience This program is intended for primary care and family medicine physicians, internists, geriatricians, nurse practitioners and other healthcare professionals interested in dementia. Objectives After participation in this session, attendees will be able to: 1) recognize Alzheimer’s disease in minority patients, 2) discuss office evaluation and management of dementia, and 3) utilize culturally competent treatment strategies throughout different stages of AD, and provide support for the caregivers of minority patients with dementia.
The William E. Matory, Jr. Memorial Symposium Addressing the Challenges of Cardiometabolic Risks: A Look at Diabetes and Atherosclerosis Approximately 20.8 million people in the United States (about 7% of the US population) have diabetes. About 14.6 million of these individuals are diagnosed with diabetes, but 6.2 million remain undiagnosed. By 2010, the prediction is that approximately 10% of the US population will have diabetes. There is now very little doubt that a huge contributory factor to the epidemic of type 2 diabetes is the epidemic of obesity.
Following participation in this session, attendees should be able to: 1) identify cardiometabolic risk factors in type 2 diabetes, such as obesity and dyslipidemia; 2) evaluate interventions that impact the progression of cardiometabolic risk in patients with Type 2 Diabetes; 3) identify patients requiring weight reduction intervention and predictors of morbidity; and 4) discuss the parameters of lipid components and recommended levels to reduce cardiometabolic risk.
Combined Session with the Physical Medicine and Rehabilitation Section The incidence and prevalence rates of Alzheimer’s disease (AD) among African Americans have been reported to be more than twice as high as the rates in white (non- Hispanic) Americans. Despite the prevalence of AD in the African-American community, there is often a delay in diagnosis and treatment. Studies have demonstrated that African Americans with AD have, on average; more sever dementia at the time of initial diagnosis. Early recognition and treatment of AD are essential to maximize patient benefits and outcomes, including cognition and function. It is therefore important to eliminate barriers to diagnosis and treatment. This session will review the physiological and anatomical changes that characterize aging in African Americans and then consider the strategies which have been employed to delay, prevent or manage relative to associated cognitive impairment.
Following participation in this session, attendees should be able to: 1) recognize Alzheimer’s disease in African Americans; 2) discuss office evaluation and management of memory loss in patients with AD; 3) utilize pharmacologic treatment strategies throughout different stages of AD, and 4) discuss support for the caregiver throughout the stages of Alzheimer disease.
Supported by an educational grant from Eisai, Inc.
Intended Audiences: Primary care physicians, family medicine, geriatricians, internal medicine, residents, nurse practitioners, physician assistants and other allied health care professionals.
Learning Objectives: Following participation in this session, attendees should be able to:
Identify the pathogenesis and neurobiology of AD;
Discuss multimodal approaches to managing AD, including neurotransmitter
modulation with ChEIs and MNDA antagonis, amelioration of behavioral and psychological symptoms of dementia with psychotropic agents;
Review the importance of alliances between healthcare providers and family caregivers;
Discuss the importance of early recognition/diagnosis of AD and other dementias; and
Utilize appropriate treatment strategies for managing patients in difference stages of AD.
This symposium is made possible by educational grants from Pfizer, Inc. and CV Therapeutics
Intended Audience Primary Care, family medicine and internal medicine physicians, cardiologists, residents, nurse practitioners, physician assistants and other allied health care professionals.
Learning Objectives Following participation in this session, attendees should be able to:
identify Framingham risk and novel and emerging risk factors in assessing patients;
evaluate the patient with combined hypertension and hyperlipidemia;
review evidenced-based treatment of diabetes as a cardiovascular risk equivalent and new approaches to glucose, lipid and blood pressure control; and
evaluate best practices to diagnose the high risk patient using invasive and non-invasive imaging including echo, nuclear imaging and cardiac catheterization.
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the United States. The Center for Disease Control reported an estimated 124,816 deaths in the United States in 2002. By 2020, COPD is expected to be the third leading cause of death for both men and women. The number of deaths from COPD has risen dramatically over the last 30 years despite recent medical advances. Compared to other leading causes of mortality (such as coronary artery disease, stroke, other heart diseases), the mortality rate from COPD is the only one that is increasing. It is an unrecognized epidemic in the United States.
Men are more likely to be diagnosed with COPD, but the prevalence among women is rising, and although African Americans have lower mortality and prevalence rates than whites, they tend to have higher rates of hospitalization and emergency room visits. They also have similar disease severity at an earlier age compared with white COPD patients. The National, Heart, Lung, and Blood Institute reports 12.1 million adults were diagnosed in 2001 (the current estimate is 16 million). There may be as many as another 14 million people in the United States, undiagnosed, as their symptoms are not severe enough to seek medical attention. This underscores the importance of primary care physicians being vigilant in looking for this problem in all smokers or patients at risk.
Needs Assessment: Type 2 diabetes is a global epidemic, it has a dramatic impact on both the international and national health care landscape due to the sheer number of people affected by the disease, an estimated 300 million people worldwide will be diagnosed with diabetes by 2025.1 In the United States (U.S.) diabetes and its complications is the fifth leading cause of death by disease.2 The quality of life implications and economic costs associated with this disease are tremendous.
The effective pharmacotherapy of type 2 diabetes mellitus continues to pose a significant challenge to primary care physicians. Newer treatment agents, such as incretin mimetics and dipeptidyl peptidase IV (DPP-IV) inhibitors, have the potential to improve glycemic control when used alone or in combination with other glucose lowering agents.
This seminar will provide clinicians with the tools necessary to ensure successful utilization of these agents in the ambulatory setting.
Positioning Incretin Therapies in Type 2 Diabetes Management: Where Do They Fit Supported by an educational grant from Merck & Co., Inc.
Needs Assessment: Type 2 diabetes is a global epidemic, it has a dramatic impact on both the international and national health care landscape due to the sheer number of people affected by the disease, an estimated 300 million people worldwide will be diagnosed with diabetes by 2025.1 In the United States (U.S.) diabetes and its complications is the fifth leading cause of death by disease.2 The quality of life implications and economic costs associated with this disease are tremendous.
The effective pharmacotherapy of type 2 diabetes mellitus continues to pose a significant challenge to primary care physicians. Newer treatment agents, such as incretin mimetics and dipeptidyl peptidase IV (DPP-IV) inhibitors, have the potential to improve glycemic control when used alone or in combination with other glucose lowering agents.
This seminar will provide clinicians with the tools necessary to ensure successful utilization of these agents in the ambulatory setting.
Continuing Medical Education: The National Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Medical Association designates this continuing medical education activity for a maximum of 26.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The National Medical Association CME Activity “Internal Medicine Seminar” of the National Medical Association has been reviewed and approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1620 I Street, NW, Suite 615, Washington, DC 20006. The National Medical Association has awarded 2.6 of CEU’s to participants who successfully complete this program. Statement of Disclosure: Faculty for the National Medical Association programs are expected to disclose at the beginning of their educational presentation any relevant financial relationships with the commercial company. Disclaimer: The National Medical Association (NMA) and its staff are not responsible for injury or illness resulting from the use of medications or modalities discussed during this educational activity. The NMA does not endorse the use of off-labeled medications.
At the conclusion of the program, the attendees should to able to:
understand risk factor assessment utilizing formal (i.e. Framingham Risk Scoring, etc.) and less formal assessment instruments and techniques;
recognize not only the dominant role that hypertension plays in African American patients’ risk but the important additive role of other CV risk factors such as dyslipidemia, overweight and obesity, glucose intolerance and diabetes, and other risk factors; and
design and apply aggressive treatment strategies early and to utilizing data from clinical trials and other evidenced-based research on which to support their clinical decision making.
Latest Clinical Trials and Best Practice Strategies for the Primary Care Physician This program is made possible by an educational grant from Bristol-Myers Squibb Company/Sanofi-Synthelabo Partnership.
Learning Objectives At the conclusion of this session, participants should be able to:
understand the impact of undiagnosed and inadequately treated risk factors on producing target organ damage with resulting morbidity and mortality;
be familiar with the most recent clinical trials and treatment modalities for the risk factors and early target organ disease; and
diagnose early, treat promptly and refer expeditiously patients who present with risk factors and early signs of malfunction and damage in the various target organs.
Intended Audience Primary Care physicians, family medicine, internal medicine, residents, nurse practitioners, physician assistants and other allied health care professionals.
Learning Objectives At the conclusion of this session, participants should be able to:
Discuss the impact of uncontrolled blood pressure on morbidity and mortality in the U.S., especially among African Americans;
Utilize the most recent national data (NHANES 1999-2000) on blood pressure awareness, treatment and control;
Identify hypertensive patients who are more challenging or difficult to control goal pressures; and
Discuss how to achieve goal blood pressures more frequently in these diverse populations.
Overall Objectives: At the completion this educational activity, the attendee should be able to: 1) recognize the benefits of using the new generation mental health medications to treat African American and other disparate patient populations; 2) understand the relevant drug metabolism interactions inherent in treating African American patients with atypical agents used for treating mental illnesses; 3) utilize the needed clinical strategies to address medically co-morbid conditions within a psychiatric practice; 4) identify the best-practice models/techniques for the diagnosis and evidence-based treatment of African American, other ethnic minority and priority patient populations; and 5) apply diagnostic and screening techniques/tools.
The National Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Medical Association designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s) TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
DIABETES MANAGEMENT SYMPOSIUM
The William E. Matory, Jr. Memorial Symposium
Combined Session with the Physical Medicine and Rehabilitation Section
Supported by an educational grant from 
Needs Assessment:
Positioning Incretin Therapies in Type 2 Diabetes Management: Where Do They Fit
Disparities and Cardiovascular Risk Stratification in Minority
Continuing Medical Education: 
Latest Clinical Trials and Best Practice Strategies for the Primary Care Physician
Intended Audience
